{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:05:46Z","timestamp":1787785546814,"version":"build-2784847793"},"reference-count":34,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:p>Background: Recessive pathogenic variants in LAMA2 resulting in complete or partial loss of laminin \u03b12 protein cause congenital muscular dystrophy (LAMA2 CMD). The prevalence of LAMA2 CMD has been estimated by epidemiological studies to lie between 1.36\u201320 cases per million. However, prevalence estimates from epidemiological studies are vulnerable to inaccuracies owing to challenges with studying rare diseases. Population genetic databases offer an alternative method for estimating prevalence. Objective: We aim to use population allele frequency data for reported and predicted pathogenic variants to estimate the birth prevalence of LAMA2 CMD. Methods: A list of reported pathogenic LAMA2 variants was compiled from public databases, and supplemented with predicted loss of function (LoF) variants in the Genome Aggregation Database (gnomAD). gnomAD allele frequencies for 273 reported pathogenic and predicted LoF LAMA2 variants were used to calculate disease prevalence using a Bayesian methodology. Results: The world-wide birth prevalence of LAMA2 CMD was estimated to be 8.3 per million (95% confidence interval (CI) 6.27 \u201310.5 per million). The prevalence estimates for each population in gnomAD varied, ranging from 1.79 per million in East Asians (95% CI 0.63 \u20133.36) to 10.1 per million in Europeans (95% CI 6.74 \u201313.9). These estimates were generally consistent with those from epidemiological studies, where available. Conclusions: We provide robust world-wide and population-specific birth prevalence estimates for LAMA2 CMD, including for non-European populations in which LAMA2 CMD prevalence hadn\u2019t been studied. This work will inform the design and prioritization of clinical trials for promising LAMA2 CMD treatments.<\/jats:p>","DOI":"10.3233\/jnd-221552","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:58:17Z","timestamp":1680263897000},"page":"381-387","source":"Crossref","is-referenced-by-count":18,"title":["Estimating the Prevalence of LAMA2 Congenital Muscular Dystrophy using Population Genetic Databases"],"prefix":"10.1177","volume":"10","author":[{"given":"Nicole J.","family":"Lake","sequence":"first","affiliation":[{"name":"Yale School of Medicine, New Haven, CT, USA"},{"name":"Murdoch Children\u2019s Research Institute, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Phua","sequence":"additional","affiliation":[{"name":"Masters Program in Biotechnology, UCSI University, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Program of Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristen","family":"Moors","sequence":"additional","affiliation":[{"name":"Prothelia Therapeutics, Milford, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Axon","sequence":"additional","affiliation":[{"name":"Prothelia Therapeutics, Milford, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monkol","family":"Lek","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JND-221552_ref1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/bs.ctm.2015.05.002","article-title":"Laminin-alpha2 Chain-Deficient Congenital Muscular Dystrophy: Pathophysiology and Development of Treatment","volume":"76","author":"Durbeej","year":"2015","journal-title":"Curr Top Membr"},{"issue":"2","key":"10.3233\/JND-221552_ref2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ng1095-216","article-title":"Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy","volume":"11","author":"Helbling-Leclerc","year":"1995","journal-title":"Nat Genet"},{"issue":"10","key":"10.3233\/JND-221552_ref3","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/humu.23599","article-title":"LAMA2 gene mutation update: Toward a more comprehensive picture of the laminin-alpha2 variome and its related phenotypes","volume":"39","author":"Oliveira","year":"2018","journal-title":"Hum Mutat"},{"issue":"44","key":"10.3233\/JND-221552_ref4","doi-asserted-by":"crossref","first-page":"27664","DOI":"10.1074\/jbc.271.44.27664","article-title":"Structure of the human laminin alpha2-chain gene (LAMA2), which is affected in congenital muscular dystrophy","volume":"271","author":"Zhang","year":"1996","journal-title":"J Biol Chem"},{"key":"10.3233\/JND-221552_ref5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fnmol.2020.00123","article-title":"LAMA2-Related Dystrophies: Clinical Phenotypes, Disease Biomarkers, and Clinical Trial Readiness","volume":"13","author":"Sarkozy","year":"2020","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"10.3233\/JND-221552_ref6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12883-021-02336-z","article-title":"Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: Protocol of the LAST STRONG study","volume":"21","author":"Bouman","year":"2021","journal-title":"BMC Neurology"},{"key":"10.3233\/JND-221552_ref7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/TACG.S187481","article-title":"Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-alpha2 chain-deficient congenital muscular dystrophy","volume":"12","author":"Nguyen","year":"2019","journal-title":"Appl Clin Genet"},{"issue":"7767","key":"10.3233\/JND-221552_ref8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-019-1430-x","article-title":"A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene","volume":"572","author":"Kemaladewi","year":"2019","journal-title":"Nature"},{"key":"10.3233\/JND-221552_ref9","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.nmd.2017.06.060","article-title":"Congenital muscular dystrophy ascending multiple dose cohort study analyzing pharmacokinetics at three dose levels in children and adolescents with assessment of safety and tolerability of omigapil (CALLISTO) trial update","volume":"27","author":"Leach","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"13","key":"10.3233\/JND-221552_ref10","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/hmg\/ddaa104","article-title":"Laminin-111 protein therapy after disease onset slows muscle disease in a mouse model of laminin-alpha2 related congenital muscular dystrophy","volume":"29","author":"Barraza-Flores","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JND-221552_ref11","doi-asserted-by":"crossref","unstructured":"Reinhard JR , Lin S , McKee KK , Meinen S , Crosson SC , Sury M , et al. Linker proteins restore basement membrane and correct LAMA2-related muscular dystrophy in mice, Sci Transl Med. (2017);9(396).","DOI":"10.1126\/scitranslmed.aal4649"},{"issue":"1","key":"10.3233\/JND-221552_ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-8966(99)00055-3","article-title":"Neuromuscular disorders in childhood: A descriptive epidemiological study from western Sweden","volume":"10","author":"Darin","year":"2000","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.3233\/JND-221552_ref14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF02185752","article-title":"Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy","volume":"97","author":"Mostacciuolo","year":"1996","journal-title":"Hum Genet"},{"issue":"Pt 11","key":"10.3233\/JND-221552_ref15","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1093\/brain\/awp236","article-title":"Prevalence of genetic muscle disease in Northern England: In-depth analysis of a muscle clinic population","volume":"132","author":"Norwood","year":"2009","journal-title":"Brain"},{"issue":"6","key":"10.3233\/JND-221552_ref16","first-page":"457","article-title":"Clinical and genomic characteristics of LAMA2 related congenital muscular dystrophy in a patients\u2019 cohort from Qatar","volume":"30","author":"Abdel","year":"2020","journal-title":"A population specific founder variant. Neuromuscul Disord"},{"issue":"9","key":"10.3233\/JND-221552_ref17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/WNL.0000000000001303","article-title":"Prevalence of congenital muscular dystrophy in Italy: Apopulation study","volume":"84","author":"Graziano","year":"2015","journal-title":"Neurology"},{"issue":"D1","key":"10.3233\/JND-221552_ref19","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: Improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.3233\/JND-221552_ref20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/humu.21438","article-title":"LOVD v.2.0: The next generation in gene variant databases","volume":"32","author":"Fokkema","year":"2011","journal-title":"Hum Mutat"},{"issue":"12","key":"10.3233\/JND-221552_ref21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/humu.23615","article-title":"hgvs: A Python package for manipulating sequence variantsusing HGVS nomenclature: Update","volume":"39","author":"Wang","year":"2018","journal-title":"Hum Mutat"},{"issue":"1","key":"10.3233\/JND-221552_ref22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl Variant Effect Predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome biology"},{"issue":"7809","key":"10.3233\/JND-221552_ref23","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.3233\/JND-221552_ref24","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1101\/gr.229102","article-title":"The human genome browser at UCSC","volume":"12","author":"Kent","year":"2002","journal-title":"Genome Res"},{"issue":"7571","key":"10.3233\/JND-221552_ref25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Genomes Project","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.3233\/JND-221552_ref27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1399-0004.2008.01068.x","article-title":"LAMA2 gene analysis in a cohort of 26 congenital muscular dystrophy patients","volume":"74","author":"Oliveira","year":"2008","journal-title":"Clin Genet"},{"issue":"3","key":"10.3233\/JND-221552_ref28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JND-150093","article-title":"Laminin alpha2 Deficiency-Related Muscular Dystrophy Mimicking Emery-Dreifuss and Collagen VI related Diseases","volume":"2","author":"Nelson","year":"2015","journal-title":"Journal of neuromuscular diseases"},{"key":"10.3233\/JND-221552_ref29","doi-asserted-by":"crossref","first-page":"719437","DOI":"10.3389\/fgene.2021.719437","article-title":"The Estimated Prevalence of N-Linked Congenital Disorders of Glycosylation Across Various Populations Based on Allele Frequencies in General Population Databases","volume":"12","author":"Pajusalu","year":"2021","journal-title":"Frontiers in Genetics"},{"key":"10.3233\/JND-221552_ref30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fgene.2017.00167","article-title":"Departure from Hardy Weinberg Equilibrium and Genotyping Error","volume":"8","author":"Chen","year":"2017","journal-title":"Frontiers in Genetics"},{"issue":"2","key":"10.3233\/JND-221552_ref31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JND-140031","article-title":"Reviewing Large LAMA2 Deletions and Duplications in Congenital Muscular Dystrophy Patients","volume":"1","author":"Oliveira","year":"2014","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"7809","key":"10.3233\/JND-221552_ref32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-020-2287-8","article-title":"A structural variation reference for medical and population genetics","volume":"581","author":"Collins","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.3233\/JND-221552_ref33","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.nmd.2021.11.004","article-title":"The version of the gene table of neuromuscular disorders (nuclear genome)","volume":"31","author":"Cohen","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.3233\/JND-221552_ref34","doi-asserted-by":"crossref","unstructured":"Zambon AA , Muntoni F Congenital muscular dystrophies: What is new? Neuromuscul Disord (2021);31(10):931\u201342.","DOI":"10.1016\/j.nmd.2021.07.009"},{"issue":"2","key":"10.3233\/JND-221552_ref35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.ejhg.5200743","article-title":"Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#25, LAMA2 gene coding for alpha2 chain of laminin)","volume":"10","author":"Allamand","year":"2002","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"10.3233\/JND-221552_ref36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.nmd.2004.06.009","article-title":"The congenital muscular dystrophies in A century of exciting progress","volume":"14","author":"Muntoni","year":"2004","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.3233\/JND-221552_ref37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.nmd.2017.06.008","article-title":"Congenital muscular dystrophies in the UK population: Clinical and molecular spectrum of a large cohort diagnosed over a 12-year period","volume":"27","author":"Sframeli","year":"2017","journal-title":"Neuromuscul Disord"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-221552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:52:23Z","timestamp":1777506743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-221552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":34,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jnd-221552","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}